Moreover, leveraging high-throughput screening, we have identified the small molecule retigabine as an effective agent that mitigates CIH-mediated NASH progression by inhibiting the degradation of Eepd1 (Figure 1). The gene discussed is EEPD1; the disease is metabolic dysfunction-associated steatohepatitis.